Chennai: Researchers at the Indian Institute of Technology-Madras (IIT-M) have identified a sustainable and high-yielding alternative source for the anti-cancer drug Camptothecin.
A press release from IIT-M said this novel microbial fermentation process can be an economically-efficient method of production to fulfil the market demand at large scale.
Topotecan and Irinotecan are two widely used anticancer drugs, which are produced by using Camptothecin as the lead molecule.
IIT-Madras researchers have now developed an alternative method of Camptothecin production to meet the demand and conserve the natural sources.
To this effect, they developed a microbial fermentation process that can be an economically efficient and sustainable method of production to fulfil the market demand at large scale.
The research was led by Dr Smita Srivastava, Associate Professor, Department of Biotechnology, IIT Madras.
This work was published in the reputed peer-reviewed International Journal of Scientific Reports (a Nature Research Publication).
Dr Smita Srivastava said ‘the novelty of the work lies in the fact that unlike other potential microbial strains reported, this strain has been found to show sustainable production even beyond 100 generations. The plan now is
to use the isolated novel strain for the development of a microbial fermentation based sustainable bioprocess for large scale in vitro production of Camptothecin, preferably in collaboration with interested Industrial partner(s)’.
High demand, low supply
More than a dozen derivatives and conjugates of Camptothecin are under various stages of clinical trials for anti-cancer applications. Camptothecin is an alkaloid isolated from the Chinese tree Camptotheca acuminata and the Indian tree Nothapodytes nimmoniana.
Nearly 1,000 tons of plant material is required to extract just one ton of Camptothecin.
Due to extensive over-harvesting to meet the market demand both these plants are now critically endangered.
